Tag: Antiretroviral

According to manufacturers and medical experts, there is no acceptable number of missed Biktarvy doses, as even a single missed pill carries risks that can affect the long-term efficacy of your HIV treatment. Maintaining strict adherence is the cornerstone of successful antiretroviral therapy (ART) to keep your viral load suppressed and prevent drug resistance.

Nelfinavir, an antiretroviral medication used to treat human immunodeficiency virus (HIV) infection, was first approved by the FDA in 1997. The generic for nelfinavir is known by its chemical name, nelfinavir mesylate, but a therapeutically equivalent generic version is currently not available in the United States.

In July 2003, the U.S. Food and Drug Administration (FDA) approved the once-daily HIV medication **Emtriva**. The biopharmaceutical company Gilead Sciences, Inc. holds the trademark and is responsible for the manufacturing and marketing of this essential antiretroviral drug.

In 1987, azidothymidine (AZT) became the first FDA-approved medication for treating HIV/AIDS, marking a pivotal moment in the fight against the virus. Understanding **how does AZT affect viral replication?** is key to appreciating this drug's historical and pharmacological significance in HIV management.

According to studies like the ADVANCE trial, individuals on regimens containing dolutegravir and tenofovir alafenamide (TAF) experience significantly greater weight gain than those on older treatments. The question of which antiretroviral causes weight gain is increasingly important as modern therapies improve health outcomes but present new metabolic challenges.

Enfuvirtide, commonly known by its research code T20 and brand name Fuzeon, was the first-in-class HIV fusion inhibitor approved by the FDA in 2003, marking a significant milestone in antiretroviral therapy. This potent peptide drug revolutionized treatment for individuals with drug-resistant HIV by uniquely blocking the virus from entering healthy immune cells. However, the term 'T20' also appears as a pill imprint for many other medications, which can cause confusion.

While the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine has a significantly lower risk of causing peripheral neuropathy compared to older agents like stavudine, it can still occur as a side effect. This condition can manifest as numbness, tingling, or burning sensations, primarily in the hands and feet.

NRTIs, or nucleoside reverse transcriptase inhibitors, were the first class of antiretroviral drugs to be approved by the FDA for HIV treatment, marking a monumental step in managing the infection. Understanding what is the mechanism of action of NRTI is crucial for comprehending how these foundational drugs work to combat the virus at its core.

First approved by the FDA in 2003, emtricitabine (FTC) is a nucleoside reverse transcriptase inhibitor (NRTI). This classification places it among the essential antiretroviral drugs used in combination to treat and prevent HIV infection, leveraging its unique mechanism to block viral replication.

Emtricitabine is a cornerstone of modern antiretroviral therapy (ART) and HIV pre-exposure prophylaxis (PrEP), widely used in combination with other medications. So, what class of antiviral is emtricitabine? It belongs to the nucleoside reverse transcriptase inhibitor (NRTI) drug class.